CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade SpringWorks Therapeutics, Inc. - SWTX CFD

36.51
2.42%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.21
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-4.63)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 37.65
Open 37.37
1-Year Change 10.17%
Day's Range 36.74 - 37.63
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 37.65 0.13 0.35% 37.52 38.64 37.33
Dec 16, 2024 37.92 -0.01 -0.03% 37.93 38.75 37.31
Dec 13, 2024 38.25 0.01 0.03% 38.24 38.39 37.20
Dec 12, 2024 38.62 -0.72 -1.83% 39.34 40.05 38.22
Dec 11, 2024 39.70 -1.86 -4.48% 41.56 41.70 39.68
Dec 10, 2024 41.58 0.79 1.94% 40.79 42.24 40.79
Dec 9, 2024 41.83 0.63 1.53% 41.20 42.44 40.94
Dec 6, 2024 41.48 -0.25 -0.60% 41.73 42.84 41.07
Dec 5, 2024 41.70 -0.36 -0.86% 42.06 42.54 41.05
Dec 4, 2024 42.25 -0.05 -0.12% 42.30 44.79 42.09
Dec 3, 2024 42.47 1.32 3.21% 41.15 42.54 40.95
Dec 2, 2024 41.82 0.57 1.38% 41.25 41.99 40.72
Nov 29, 2024 41.43 0.13 0.31% 41.30 41.72 40.80
Nov 27, 2024 41.68 0.30 0.72% 41.38 42.25 40.91
Nov 26, 2024 41.17 1.85 4.70% 39.32 41.61 39.32
Nov 25, 2024 39.33 0.26 0.67% 39.07 40.65 39.02
Nov 22, 2024 38.96 2.90 8.04% 36.06 39.56 36.05
Nov 21, 2024 36.23 -1.02 -2.74% 37.25 37.47 36.11
Nov 20, 2024 37.38 -0.51 -1.35% 37.89 38.15 36.65
Nov 19, 2024 37.88 3.65 10.66% 34.23 37.89 34.23

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

SpringWorks Therapeutics, Inc. Company profile

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for underserved patient populations suffering from devastating rare diseases and cancer. It has a portfolio of small molecule targeted oncology product candidates and are advancing two clinical trials in rare tumor types, as well as other programs addressing genetically defined cancers. Its product candidate is nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in development as a monotherapy for the treatment of desmoid tumors, a rare and often debilitating and disfiguring soft tissue tumor. Its second product candidate is mirdametinib, an oral, small molecule MEK inhibitor in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), a rare tumor of the peripheral nerve sheath that causes pain and disfigurement, and that most often manifests in children.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, SpringWorks Therapeutics Inc revenues decreased from $35M to $0K. Net loss increased from $45.6M to $173.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Biopharmaceutical segment loss increase from $46.3M to $173.5M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.05 to -$3.59.

Industry: Bio Therapeutic Drugs

100 Washington Blvd
STAMFORD
CONNECTICUT 06902-9302
US

People also watch

Gold

2,617.00 Price
-0.770% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

2.47 Price
-4.530% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01232

BTC/USD

103,674.30 Price
-2.060% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

US100

21,804.20 Price
-0.330% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading